secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2026-03-13T23:59:59+00:00
Accession:  0001213900-26-027281
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 5.03, 2.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt acquires Ignite Proteomics for $36M in preferred stock; issues $3.2M notes
--------------------------------------------------------------------------------

- Acquired 100% of Ignite Proteomics for 36,000 Series A-2 Convertible Preferred Shares (stated value $36M).
- Ignite's RPPA platform measures protein expression for therapy selection; CLIA lab, Medicare PLA ~$2,200/test.
- Closed $3.2M note purchase (10% OID) with $2.875M funding; 6% interest, 9-month maturity, prepayable.
- Company believes it regained compliance with Nasdaq minimum stockholders' equity requirement ($2.5M) after acquisition.
- Ignite plans to launch program in 2026 targeting >600,000 US metastatic cancer patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390026027281/0001213900-26-027281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390026027281/ea0279443-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-027281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer